Like this article?
Get your free daily medical news from Physician's First Watch.
Vytorin Yields Mixed Outcomes
Vytorin (simvastatin plus ezetimibe) reduces atherosclerotic events in patients with aortic stenosis — but has no effect on aortic-valve events — researchers reported at a press conference earlier this week.
The industry-funded SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study randomized nearly 1900 patients with mild-to-moderate aortic stenosis to Vytorin or placebo. During roughly 4 years' follow-up, the primary endpoint — a composite of atherosclerotic and aortic-valve events — did not differ between the groups. In secondary analyses, atherosclerotic events alone were lower with Vytorin than with placebo (16% vs. 20%), but aortic-valve events were not reduced.
Cancer was observed more often with Vytorin than with placebo (10% vs. 7%); however, the researchers note that data from larger studies do "not support the suggestion of an increase in cancer" with the drug.
To date, the SEAS data have not been presented at a meeting or published in a journal.
LINK(S):
SEAS press release (Free PDF)
Archived Vytorin webcast (Free)
New York Times story (One-time registration required)
Published in Physician's First Watch July 23, 2008
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.